Hsu PI, et al. - In a randomized trial, researchers ascertained the efficacies of reverse hybrid therapy vs bismuth quadruple therapy as first-line treatments for patients with H pylori infection. No significant differences were evident between therapies regarding eradication of clarithromycin-resistant strains or metronidazole-resistant strains. Thereby suggesting that 14-day reverse hybrid therapy was not inferior to bismuth quadruple therapy as a first-line treatment for H pylori infection. Fewer adverse events were observed in association with reverse hybrid therapy.